RLYB — Rallybio Income Statement
0.000.00%
Last trade - 00:00- $12.19m
- -$53.32m
- $0.64m
- 17
- 33
- 21
- 12
Annual income statement for Rallybio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0 | 0.636 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 26.8 | 47.2 | 69 | 81 | 63.4 |
| Operating Profit | -26.8 | -47.2 | -69 | -81 | -62.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -26.5 | -47 | -66.7 | -74.6 | -57.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -26.4 | -47 | -66.7 | -74.6 | -57.8 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -26.4 | -47 | -66.7 | -74.6 | -57.8 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -26.4 | -47 | -66.7 | -74.6 | -57.8 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -9.57 | -1.78 | -2.06 | -1.79 | -1.28 |